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Abstract: Despite the significant therapeutic advances achieved with proteasome inhibitors 
(PIs) such as bortezomib and carfilzomib in prolonging the survival of patients with multiple 
myeloma, the development of drug resistance, peripheral neuropathy, and pharmacokinetic 
limitations continue to pose major challenges when using these compounds. Ixazomib is a 
second-generation PI with improved activity over other PIs. Unlike bortezomib and carfilzomib, 
which are administered by injection, ixazomib is the first oral PI approved by US Food and 
Drug Administration. This review discusses the biochemical properties, mechanisms of action, 
preclinical efficacy, and clinical trial results leading to the US Food and Drug Administration 
approval of ixazomib.
Keywords: proteasome inhibitor, oral administration, biological mechanism, clinical trials
Introduction
Multiple myeloma (MM) is a disorder of clonal cells that aggregate in the bone marrow 
(BM) stromal compartment. The MM cells are characterized by immune dysfunc-
tion, deregulated cell signaling, and high secretion of monoclonal protein detectable 
in the blood and/or urine.1,2 MM primarily affects older individuals with a mean age 
of diagnosis between 63 years and 70 years of age.3 The disease constitutes 1.5% of 
all cancers and almost 15% of all hematological malignancies. There are ∼86,000 
new cases of MM occurring worldwide each year, with MM accounting for an esti-
mated 11,090 deaths in the US in 2014 and an estimated 10,390 deaths in Europe in 
2012.4 The introduction of the novel agents, including proteasome inhibitors (PIs) 
(bortezomib – Velcade and carfilzomib – Kyprolis) and immunomodulatory drugs 
(thalidomide – Thalomid, lenalidomide – Revlimid, and pomalidomide – Pomalyst), 
was an important advance in the therapy of MM.5,6 The combination regimens of 
these drugs and autologous stem cell transplantation substantially extended the aver-
age MM patient survival.3 Bortezomib was the first PI approved by the US Food and 
Drug Administration (FDA) in 2003 for relapsed/refractory MM patients, and also a 
few years later for treating newly diagnosed MM patients.7
Despite revolutionizing the treatment of MM, there are several limitations for the 
bortezomib treatment, including 1) not every MM patient will respond to bortezomib 
as a first-line therapy; 2) the majority of patients who initially respond favorably to 
bortezomib may later develop drug resistance and relapse; 3) peripheral neuropa-
thy (PN) is a dose-limiting toxicity of bortezomib, which can potentially result in 
permanent nerve damage to the extremities;8 and 4) other common side effects of bort-
ezomib include fatigue, gastrointestinal effects, and modest cytopenias.8 Bortezomib 
is administered intravenously (iv) and recently subcutaneously (sc), which showed 
similar bioavailability with noninferior efficacy and a significantly lower incidence of 
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PN compared to iv administration.9–12 Moreover, the safety 
profile of bortezomib was further improved by reducing 
dosing frequency from twice weekly to once weekly.13 A 
second-generation PI, carfilzomib, was approved by the US 
FDA in 2012 for the treatment of MM patients. Carfilzomib 
offered a therapeutic benefit to a fraction of patients who 
relapsed from bortezomib treatment while showing decreased 
PN.14 Nonetheless, drug resistance was also observed fol-
lowing carfilzomib treatment.15 One likely contributor to this 
resistance is the drug efflux pump P-glycoprotein (P-gp). 
Carfilzomib is a known P-gp substrate, and a few studies 
have demonstrated that carfilzomib-resistant cells exhibited 
increased P-gp expression.16–18 A significant limitation of the 
treatment with bortezomib and carfilzomib is that both these 
drugs are administered iv, which implies the need for health 
care professionals to administer the dose in a clinic or a hos-
pital, which inevitably reduces the patient’s quality of life and 
increases the treatment costs.19 Ixazomib (Ninlaro) is a small 
molecule PI that overcomes the aforementioned limitations 
of bortezomib and carfilzomib. In November 2015, ixazomib 
became the first orally administered PI to be approved by the 
US FDA. In this review, we highlight the chemical properties, 
biological activity, and mechanism of action of ixazomib, 
as well as summarize the clinical trials to test its efficacy in 
patients with MM.
Chemical structure and mechanism 
of action of ixazomib
Ixazomib (formerly known as MLN9708) was developed 
through a large-scale screening of boron-containing PIs 
with physiochemical properties distinct from bortezomib, in 
pursuit of efficacious PIs with increased efficacy and reduced 
side effects.20–22
Bortezomib structurally resembles dipeptide 
phenylalanine–leucine in which the terminal carboxylic acid 
is replaced by boric acid (Table 1).23 Bortezomib is a slowly 
reversible inhibitor of the β1 caspase-like subunit and β2 
trypsin-like subunit, with preference to the β5 chymotrypsin-
like subunit of 20S proteolytic site of proteasome.21,24 
Inhibition of the catalytic β5 site occurs when the boric acid 
group forms covalent bound with the hydroxyl group of the 
N-terminal threonine residue.22,25 On the other hand, carfil-
zomib has a tripeptide backbone containing phenylalanine, 
leucine, and homophenylalanine with terminal epoxyketone 
group (Table 1).23,26 Carfilzomib is an irreversible inhibitor 
with high specificity for the β5 chymotrypsin-like subunit 
of the proteasome.27 Ixazomib belongs to the same structural 
class and acts through the same mechanism as bortezomib. 
Ixazomib consists of an alanine–leucine dipeptide core with 
a citrate-protected boric acid and preferentially inhibits the 
β5 chymotrypsin-like subunit of proteasome, which cleaves 
proteins after hydrophobic residues. Furthermore, at high 
concentrations, ixazomib is capable of inhibiting other prote-
olytic sites of 20S proteasome, including the β1 caspase-like 
subunit, which cleaves proteins after acidic residues, and 
β2 trypsin-like subunit, which cleaves after basic residues 
(Table 1 and Figure 1).22
Ixazomib is a citrate ester of boronic acid, which when 
exposed to aqueous solutions (eg, gastrointestinal tract and 
plasma) hydrolyzes to free boric acid metabolite MLN2238 
that carries the biological effect (Figure 1).21 Xenograft 
mouse models demonstrated that ixazomib has significantly 
higher antitumor activity, which is attributed to distribution 
of larger blood volume compared to bortezomib, conferring 
greater pharmacodynamics.21,22 The clinical trials of ixazomib 
showed low incidence of PN compared to bortezomib, which 
may be ascribed to the high specificity of ixazomib in inhib-
iting the chymotrypsin-like site of the 20S proteasome.21,28 
Moreover, ixazomib elicits therapeutic response in patients 
who were bortezomib resistant.14,20
Biological mechanisms of ixazomib
Cell signaling pathways
In vitro studies performed with different human MM cell 
lines treated with various concentrations of ixazomib showed 
a concentration-dependent decrease in the viability of all 
treated cell lines. Furthermore, it was shown that ixazomib 
induced apoptosis of MM cell lines resistant to conventional 
therapies and in primary MM cells obtained from bortezomib- 
and lenalidomide-resistant patients.20 The apoptotic activity 
of ixazomib was mediated by the activation of caspase-8, 
caspase-9, and caspase-3 and other apoptotic pathways such 
as p53–p21, p53–NOXA–PUMA, and Rb–E2F. Ixazomib 
also induced the expression of binding immunoglobulin 
protein and CCAAT-enhancer-binding protein homologous 
protein transcription factor – both connected to endoplasmic 
reticulum stress response.20
MicroRNA profiling studies with MM cells showed that 
ixazomib induced upregulation of miR33b, a tumor sup-
pressor gene that is constitutively expressed at low levels in 
MM cells. Increased miR33b expression leads to cell death 
and apoptosis by blocking proto-oncogene (PIM-1) via 
inhibiting serine/threonine kinase activity. Furthermore, this 
increased expression is associated with reduced migration 
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Antitumor activity of ixazomib in vivo
Treatment of MM-bearing mice with ixazomib induced a 
significant inhibition of MM tumor growth and a significant 
increase in survival compared to vehicle- and bortezomib-
treated mice. In accordance with the in vitro data, when com-
pared to vehicle-treated mice, ixazomib-treated mice showed 
an increase in the number of cleaved caspase-3-positive 
cells, increase in the number of TUNEL-positive cells, and 
decrease in the proliferation marker Ki-67. Immunostaining 
of harvested mouse tumors revealed that ixazomib inhibited 
the angiogenic activity of tumors and reduced the expres-
sion of angiogenesis markers such as vascular endothelial 
growth factor receptor 2 and platelet endothelial cell adhe-
sion molecule, while displaying normal levels of creatinine, 
hemoglobin, and bilirubin.20
Anti-BM microenvironment activity of 
ixazomib
Acellular components include cytokines and growth factors, 
which facilitate cell proliferation, extracellular matrix, a 
scaffold promoting cell-cell interactions, and hypoxia niche, 
which causes limited oxygen diffusion as well as alters 
gene expression promoting drug resistance.30,31 Cellular 
components include stromal cells, which facilitate adhesion 
and proliferation,32–35 endothelial cells, which create blood 
vessels thus contribute to metastasis,36 and osteoblasts/
osteoclasts, which contribute to bone lytic lesions.37,38 
In vitro, ixazomib inhibited the NF-κB pathway in MM 
stromal cells, reducing the release of cytokines that are 
vital for growth and survival of MM cells. Thus, treatment 
with ixazomib disrupts the cytoprotective effects of the BM 
Figure 1 Mechanism of action of ixazomib.
Notes: ixazomib (MLN9708) administered orally as a capsule is rapidly absorbed and hydrolyzed to the biologically active form (MLN2238) when it comes in contact with 
aqueous plasma. Ixazomib blocks protein degradation by inhibiting the 20S catalytic subunit of the 26S proteasome. More specifically, at lower concentrations, MLN2238 
inhibits the β5 chymotrypsin-like subunit, which cleaves proteins after hydrophobic residues. At high concentrations, MLN2238 inhibits the β1 caspase-like subunit and 
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Efficacy of ixazomib in myeloma
microenvironment on MM cells and inhibits proliferation 
of MM cells.20
Osteolytic lesions are the most common complication of 
MM.39 It was demonstrated that ixazomib has a positive effect 
against MM-induced bone lytic lesions, since it inhibited 
osteoclast resorption with efficiency similar to bortezomib. 
It was demonstrated that early osteoclast differentiation 
was mediated by multiple signaling pathways that involve 
NF-κB; ixazomib decreased NF-κB signaling in preosteo-
clasts by impairing the degradation of the cellular NF-κB 
inhibitor, I-κB, by inhibiting the proteasome, which con-
sequently reduced osteoclastogenesis.39 Moreover, in terms 
of osteoblast activity, ixazomib enhanced differentiation of 
osteoblast from primary mesenchymal stem cells isolated 
from myeloma and enhanced osteoblast functions.39
Pharmacokinetic and pharmacodynamic 
parameters in animal models
Biochemical analysis showed that the potency and selectiv-
ity of ixazomib and bortezomib to β1, β2, and β5 subunits 
of proteasome are of the same magnitude, with preferential 
inhibitory activity towards β5 subunit with the half maximal 
inhibitory concentration (IC
50
) for ixazomib 3.4 nmol/L and 
for bortezomib 2.4 nmol/L. The half-life (t
1/2
) of dissociation 
of ixazomib from the proteasome was found to be approxi-
mately six times shorter than that of bortezomib (18 minutes 
versus 110 minutes), which was consistent with the recovery 
of proteasome activity with bortezomib-treated cells recover-
ing slower than ixazomib-treated cells.22
However, when administered iv, ixazomib was shown 
to have superior pharmacokinetic parameters compared 
with bortezomib; the maximal plasma concentration (C
max
) 
of ixazomib was 17,000 ng/mL compared to 321 ng/mL for 
bortezomib. In addition, ixazomib provided a greater plasma 
exposure (area under the curve [AUC
0–24 h
] =8,090 h⋅ng/mL) 
compared with bortezomib (AUC
0–24 h
 =485 h⋅ng/mL), when 
both PIs were injected iv using their maximum tolerated 
doses. Moreover, ixazomib demonstrated five times higher 
drug distribution from blood into tissues supported by blood 
volume distribution, V
d
, of 20.2 L/kg compared to V
d
 =4.3 L/kg 
for bortezomib.
Ixazomib in clinical trials
Phase i clinical trial
Study design
Being the first oral PI, the clinical trials of ixazomib in 
patients with relapsed and/or refractory MM began with open-
label, Phase I dose-escalation studies and expansion cohort 
studies.19 In these studies, ixazomib was given twice weekly 
(0.24–2.23 mg/m2 on days 1, 4, 8, and 11 of a 21-day cycle) to 
60 patients who met the following criteria: .18 years old with 
a measurable disease, an absolute neutrophil count $1,000 
cells/mm3, platelet count $75,000 cells/mm3, a total bilirubin 
#1.5× the upper limit of normal, aspartate aminotransferase 
and alkaline aminotransferase #2.5× upper limit of normal, 
and creatinine clearance $20 mL/min within 3 days of receiv-
ing the first dose. The exclusion criteria included uncontrolled 
preexisting comorbidities that may interfere with the study, 
as well as the previous treatment with a PI. Dose escalation 
of ixazomib was done in a standard 3+3 scheme with the 
modified Fibonacci dose sequence. Investigators analyzed the 
dose-limiting toxicities that occurred in patients during cycle 
1 in order to determine the maximum tolerated dose.19
Toxicity and adverse effects
Of the patients who remained on the maximum tolerated dose 
of 2.0 mg/m2, or an equivalent fixed dose of 3.7 mg, ∼62% 
experienced drug-related grade $3 adverse events (AEs), 
27% of whom were grade 4. The most common drug-related 
AEs included nausea (42%), thrombocytopenia (42%), 
fatigue (40%), skin and subcutaneous tissue disorders (40%), 
vomiting (25%), diarrhea (23%), pyrexia (20%), neutropenia 
(18%), PN (12%), and chills (10%). Of the seven patients 
with drug-related PN, three patients experienced grade 1 PN 
at baseline, while others experienced a worsening of PN to 
grade 2 in cycle 2 at 0.8 mg/m2 in the cohort study, worsen-
ing from baseline while remaining at grade 1 in cycle 2 at 
1.68 mg/m2 in the cohort study, or worsening grade 2 during 
cycle 3 of the relapsed and refractory cohort.
In the dose-escalation cohort with 2.0 mg/m2 ixazomib 
given twice weekly, a patient experienced spinal cord com-
pression as a result of disease progression during cycle 1. 
In the relapsed and refractory cohort studies, five people 
discontinued treatment due to drug-related thrombocytopenia 
during cycle 1, drug-related nausea and fatigue with PN dur-
ing cycle 5, and pneumonia in cycle 2 as well as cycle 5. Two 
dose-limiting toxicities of grade 3 rash and grade 4 throm-
bocytopenia occurred with 2.23 mg/m2 of ixazomib.19
Pharmacokinetics and pharmacodynamics in Phase i 
clinical trials
Ixazomib displayed rapid absorption with a maximal concen-
tration time (T
max
) of 1 hour, C
max
 of 7.78 ng/mL, and a termi-
nal t
1/2
 of 3.3–7.4 days following a dose of 0.48 mg/m2. Linear 
pharmacokinetics was observed with a direct proportionality 
between the plasma concentration (7.78–75.9 ng/mL) and the 
administered dose (range of 0.48–2.23 mg/m2). The Phase 
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orally twice weekly was the optimal dose for efficacy and 
AEs. This dose elicited a positive response and was effective 
in controlling the disease, while the AEs were reversible, 
minor, and manageable.19
Phase ii clinical trials
Study design
Open-label Phase II trials were initiated to test the safety, 
tolerability, and efficacy of ixazomib.7 Phase II trials also 
investigated the efficacy of the addition of dexamethasone 
to the ixazomib therapy. Patients were required to be at least 
18 years, have relapsed MM after one or more attempted ther-
apies, have a measurable disease (serum M-protein $1 g/dL 
or urine M-protein $200 mg/24 hours or involved free 
light chain level $10 mg/dL), have an Eastern Coopera-
tive Oncology Group performance status of 0–2, absolute 
neutrophil count $1,000 cells/mm3, platelets $75,000 cells/
mm3, and could not be on a CYP1A2 or CYP3A4 inducer/
inhibitor within 14 days of study. The patients were also 
excluded from the study, if they experienced any of the fol-
lowing disease states: uncontrolled cardiovascular conditions 
(hypertension, cardiac arrhythmias, congestive heart failure, 
unstable angina, or myocardial infarction within the past 
6 months), HIV, positive hepatitis B surface antigen, hepa-
titis C infection, or patient allergy to any of the medications, 
analogs of the medications, or excipients that may interfere 
with the bioavailability of the drug. In total, 33 patients with 
relapsed MM were enrolled in this trial, and on average, the 
patients had previously received two alternative therapies.
The treatment goal was to receive an overall response rate 
of the drug using only a single agent in relapsed MM with 
no prior use of a PI or less than six cycles of therapy with 
a previous PI. The secondary goal was to obtain an overall 
response rate of the drug with the addition of dexamethasone. 
Patients in the Phase II study received, on average, eight 
cycles of therapy: 19 patients received four cycles, 16 patients 
received eight cycles, and the remaining 12 patients received 
12 cycles. The median dose that 27 patients received per cycle 
was 12 mg of ixazomib, ranging from 5.5 mg to 15.6 mg. Dex-
amethasone was administered at the following occasions: 1) 
at the end of cycle 2, 2) when patients showed no response to 
ixazomib alone by the end of cycle 4, or 3) if the patient experi-
enced disease progression at any point during the treatment.7
Toxicity and adverse effects
AEs experienced by patients in the Phase II trial were 
identical to those experienced in the Phase I studies – 40% 
experienced grade 3 or grade 4 and 19% experienced grade 4. 
Common AEs included thrombocytopenia, fatigue, nausea, 
and diarrhea. No patients died during the study period. 
Drug-induced grade 1 and grade 2 PN was observed in eight 
patients and five patients, respectively. No hematological 
toxicity was recorded; however, three patients discontinued 
drug therapy due to elevated stringent complete response 
(sCR) and thrombotic thrombocytopenic purpura.7
Efficacy
As a single agent, ixazomib is therapeutically effective in 
treating patients with relapsed and refractory MM, with 
minimal rates of PN. Overall, the Phase II studies showed 
that 34% of patients experienced partial response or better 
during the entire trial without the addition of dexametha-
sone. Two additional patients experienced a minor response, 
and one patient had both CR and sCR. In all, 67% of the 
patients were initiated on dual dexamethasone treatment, 
out of which, 17 patients were placed on the secondary 
therapy for not achieving a response with ixazomib alone 
and five patients were placed on the secondary therapy for 
progression of the disease. Those treated with the secondary 
therapy achieved a response rate of 34% after the dexam-
ethasone addition. Of the patients in cycle 4, five patients 
experienced a positive response to treatment, three patients 
experienced a partial response to treatment, one patient 
achieved a complete response to therapy, and one patient 
achieved an sCR.7
A number of Phase II clinical trials are evaluating a 
three-drug regimen (or more) including ixazomib, lenali-
domide, and dexamethasone for four cycles, followed by 
a randomized maintenance therapy with either ixazomib 
or lenalidomide in order to prolong the disease-free period 
in patients after stem cell transplantation (NCT02253316). 
Other randomized Phase I/II trials are testing a combination 
of ixazomib with or without pomalidomide and dexametha-
sone given together in treating patients with refractory MM 
(NCT02004275). In addition, ixazomib is being evaluated 
in previously untreated symptomatic myeloma patients 
with high risk of progression, where patients are treated in 
combination with cyclophosphamide and dexamethasone 
(NCT01864018; Table 2).
Phase iii clinical trial
There are a number of ongoing Phase III clinical trials exam-
ining the efficacy of ixazomib on progression-free survival, 
overall survival, and overall response rate at different 
stages of MM. These trials are randomized, double blinded, 
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published yet. TOURMALINE-MM1 trial is being conducted 
in 837 relapsed/refractory MM patients (NCT01564537) and 
TOURMALINE-MM2 study in .700 newly diagnosed MM 
patients (NCT01850524). In these two studies, one patient 
group receives oral ixazomib (4 mg) and the other group 
receives a placebo, while both groups receive lenalidomide 
and dexamethasone. Moreover, ixazomib (3 mg) as a single 
agent, compared to placebo, is being tested as a maintenance 
therapy in patients following autologous stem cell trans-
plantation (TOURMALINE-MM3; NCT02181413) and in 
patients who have not received autologous stem cell trans-
plantation (TOURMALINE-MM4; NCT02312258). A list 
of completed and ongoing clinical trials involving ixazomib 
in MM is given in Table 2.
Conclusion
Ixazomib is the first oral boronic acid-based PI approved by 
US FDA in combination with lenalidomide and dexametha-
sone for the treatment of MM patients who have received at 
least one prior therapy. Preclinical results demonstrated that 
ixazomib inhibits the chymotrypsin-like proteolytic (β5) site 
of the 20S proteasome, reduces tumor progression by increas-
ing MM cell apoptosis, and disrupts the interaction of MM 
cells with the BM microenvironment resulting in decreased 
angiogenesis and osteolytic lesions.
Currently, there are numerous clinical trials including 
five global Phase III trials on investigational oral ixazomib 
in MM and in other hematological malignancies such as 
lymphoma and amyloidosis, as well as in solid tumors. Based 
on study reports, ixazomib is therapeutically efficacious as 
a single agent but especially when used in combination with 
dexamethasone in the treatment of relapsed/refractory MM. 
Side effects are manageable and infrequent, including rash, 
lowered platelet and white blood cell counts, fatigue, diarrhea 
and nausea, and with a few instances of PN. By virtue of the 
convenience of oral administration, ixazomib is a promising 
option for MM treatment and is being continuously evaluated 
as a single agent or in combination with other therapies in 
Phase III trials for relapsed/refractory patients, newly diag-
nosed patients, and as a maintenance therapy.
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